Thiazolidinone Constraint Combretastatin Analogs as Novel Antitubulin Agents: Design, Synthesis, Biological Evaluation and Docking Studies
- PMID: 27141882
- DOI: 10.2174/1871520615666160504093904
Thiazolidinone Constraint Combretastatin Analogs as Novel Antitubulin Agents: Design, Synthesis, Biological Evaluation and Docking Studies
Abstract
Background: Microtubules act as a useful and strategic molecular target for various anticancer drugs that binds to its distinct sites in tubulin subunits and inhibits its polymerization and ultimately leads to cell death. Moreover, numerous reports highlight the cytotoxic effects of constraint Combretastatin analogs and thiazolidinone derivatives.
Objective: Therefore, the present study investigates the potential of thiazolidinone constraint combretastatin analogs as tubulin inhibitors.
Method: By incorporating silica supported fluroboric acid, a series of thiazolidinone constraint combretastatin analogs were synthesized in a microwave reactor under solvent free conditions. To optimize the reaction conditions, the detailed investigation was done for the catalytic influence of HBF4-SiO2. All the synthesized analogs were assessed for in-vitro cytotoxicity against THP-1, COLO-205, HCT-116 and A-549 human cancer cell lines. Top hits were further examined for their tubulin polymerization inhibition and their effect on microtubule assembly. The significant cytotoxicity and tubulin polymerization inhibition of the most potent structure was further rationalized by molecular modelling studies.
Results: The results stated that CS-2, CS-3 and CS-20 possessed significant cytotoxic potential with the IC50 values ranging from 1.21 to 5.50 μM against THP-1, COLO-205, HCT-116 human cancer cell lines. Established structure activity relationship revealed that the nature of Ring A substantially influences the cytotoxic potential of the compounds. Placement of methoxy substituents on the phenyl ring (Ring A) was found to be the most preferred structural feature. Compound CS-2 was found to considerably inhibit the tubulin polymerization (IC50 value 2.12 μM) and caused disruption of microtubule assembly as demonstrated by immunoflourescence technique. In molecular modelling studies, CS-2 exhibited various hydrophobic as well as hydrogen bonding interactions at colchicine binding site and was found to be stabilized in this cavity.
Conclusion: This work provides an efficient methodology for the synthesis of antitubulin thiazolodinonecombretastatin hybrids.
Similar articles
-
Chalcone based azacarboline analogues as novel antitubulin agents: design, synthesis, biological evaluation and molecular modelling studies.Eur J Med Chem. 2014 Oct 6;85:648-60. doi: 10.1016/j.ejmech.2014.08.005. Epub 2014 Aug 6. Eur J Med Chem. 2014. PMID: 25128667
-
New Combretastatin Analogs as Anticancer Agents: Design, Synthesis, Microtubules Polymerization Inhibition, and Molecular Docking Studies.Chem Biodivers. 2023 Apr;20(4):e202201206. doi: 10.1002/cbdv.202201206. Epub 2023 Mar 8. Chem Biodivers. 2023. PMID: 36890635
-
Triazole tethered C5-curcuminoid-coumarin based molecular hybrids as novel antitubulin agents: Design, synthesis, biological investigation and docking studies.Eur J Med Chem. 2016 Jun 30;116:102-115. doi: 10.1016/j.ejmech.2016.03.050. Epub 2016 Mar 19. Eur J Med Chem. 2016. PMID: 27060762
-
Naphthalene combretastatin analogues: synthesis, cytotoxicity and antitubulin activity.J Enzyme Inhib Med Chem. 2004 Dec;19(6):521-40. doi: 10.1080/14756360412331280473. J Enzyme Inhib Med Chem. 2004. PMID: 15662956 Review.
-
Combretastatin-based compounds with therapeutic characteristics: a patent review.Expert Opin Ther Pat. 2019 Sep;29(9):703-731. doi: 10.1080/13543776.2019.1651841. Epub 2019 Aug 8. Expert Opin Ther Pat. 2019. PMID: 31369715 Review.
Cited by
-
Design, Synthesis, and Antipoliferative Activities of Novel Substituted Imidazole-Thione Linked Benzotriazole Derivatives.Molecules. 2021 Oct 2;26(19):5983. doi: 10.3390/molecules26195983. Molecules. 2021. PMID: 34641526 Free PMC article.
-
Recent Advances of Tubulin Inhibitors Targeting the Colchicine Binding Site for Cancer Therapy.Biomolecules. 2022 Dec 10;12(12):1843. doi: 10.3390/biom12121843. Biomolecules. 2022. PMID: 36551271 Free PMC article. Review.
-
Recent advances in combretastatin based derivatives and prodrugs as antimitotic agents.Medchemcomm. 2017 Jul 4;8(8):1592-1603. doi: 10.1039/c7md00227k. eCollection 2017 Aug 1. Medchemcomm. 2017. PMID: 30108870 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources